ACADIA Pharmaceuticals Inc (NAS:ACAD)
$ 16.95 -0.42 (-2.42%) Market Cap: 2.89 Bil Enterprise Value: 2.37 Bil PE Ratio: 22.27 PB Ratio: 5.01 GF Score: 75/100

ACADIA Pharmaceuticals Inc Corporate Call - Regulatory Update on Supplemental New Drug Application Transcript

Mar 08, 2021 / 10:00PM GMT
Release Date Price: $45.78 (-6.53%)
Operator

Good day, ladies and gentlemen, and welcome to the ACADIA Pharmaceuticals conference call. My name is Mel, and I will be your coordinator for today. (Operator Instructions)

I would now like to turn the presentation over to Mark Johnson, Vice President of Investor Relations of ACADIA. Please proceed.

Mark C. Johnson
ACADIA Pharmaceuticals Inc. - VP of IR

Thank you. Joining me on today's call from ACADIA are Steve Davis, our Chief Executive Officer; and Serge Stankovic, our President, who will provide some prepared remarks before opening up the call for your questions. Also joining us today is Elena Ridloff, our Chief Financial Officer. I would also like to point out that we are using supplement slides, which are available on the Events and Presentations section of our website. Please turn to Slide 2.

Before we proceed, I would first like to remind you that during our call today, we will be making a number of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot